1. Home
  2. MRCC vs QNCX Comparison

MRCC vs QNCX Comparison

Compare MRCC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$6.63

Market Cap

151.2M

Sector

Finance

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$4.08

Market Cap

139.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
QNCX
Founded
2011
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.2M
139.2M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
MRCC
QNCX
Price
$6.63
$4.08
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$8.00
$7.75
AVG Volume (30 Days)
100.5K
946.4K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
15.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,742,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.86
$0.72
52 Week High
$8.85
$3.73

Technical Indicators

Market Signals
Indicator
MRCC
QNCX
Relative Strength Index (RSI) 57.39 81.13
Support Level $6.36 $2.92
Resistance Level $6.55 $3.73
Average True Range (ATR) 0.19 0.39
MACD 0.07 0.16
Stochastic Oscillator 98.81 89.69

Price Performance

Historical Comparison
MRCC
QNCX

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Share on Social Networks: